We're honored to be named the #1 Partner of Choice by early-stage innovators in Inpart's Biotech Partnering survey! Thank you to our partners for your trust and collaboration. Together we will transform the future of health for patients around the globe. bit.ly/3WYxZwJ

Meet Nicole. Nicole’s life changed in many ways after she was diagnosed with #PulmonaryHypertension (PH) more than a decade ago. Connecting with the PH community continues to give her the drive to live each day to its fullest. #PassionAdvancementHope #JNJCardiopulmonary

We are pleased to announce publication of results in NEJM for our investigative treatment for hemolytic disease of the fetus and newborn (HDFN), marking another step forward for those who need non-surgical options. bit.ly/3WYXfD2 #JNJImmunology

In Johnson & Johnson Innovation’s new video series, hear from some of our early-stage innovation collaborators, who lift the lid on the realities and sacrifices of life as an entrepreneur.

We are committed to preserving vision and harnessing the best science to find solutions for those living with blinding #RetinalDiseases. Learn why #GeneTherapy is at the forefront of our efforts to improve health outcomes: bit.ly/3YECyND

We won’t stop striving until we restore and preserve vision for those living with #RetinalDiseases, like X-linked retinitis pigmentosa (XLRP), a severe and progressive form of inherited vision loss. Learn about our commitment to patients with #XLRP: bit.ly/3WYzivs

#NEWS: We're pleased to announce the U.S. FDA has granted priority review of our application for a subcutaneous treatment for patients with EGFR-mutated #NSCLC. Learn more about the submission: jnj.com/media-center/p…

Your #DNA can determine if you have the potential to inherit genetic conditions, including blinding inherited retinal diseases. That's why receiving a genetic diagnosis is a fundamental step for patients. Learn more about the benefits of #GeneticTesting: eyesongenes.com/?sf197152920=1

#NEWS: The U.S. FDA has approved our chemotherapy-free combination regimen for the first-line treatment of patients living with non-small cell lung cancer (NSCLC) with specific EGFR mutations. Read about this new and important treatment option for #NSCLC: jnj.com/media-center/p…

We’re committed to transforming care for people who need it most, which is why we developed resources to help those living with #PulmonaryHypertension better understand and manage their condition. Explore our resources here: janssenwithme.com/en/pulmonary-a… #JNJCardiopulmonary

With the latest clinical data from our robust solid tumor pipeline and portfolio, we are advancing the next wave of innovative therapies for patients with cancer. Learn more about our presence at #WCLC24 and #ESMO24: jnj.com/media-center/p… #JNJOncology

We’re looking forward to attending the #ESCCongress this weekend, the world’s largest cardiovascular congress, where we’ll gather with the global CV community to discuss the latest research and advancements in cardiovascular care. Learn more: escardio.org/?sf197910661=1

#GeographicAtrophy (GA) is a progressive disease that affects over 8 million people globally. We’re working on solutions that could offer hope to those affected by GA. Read more in the AAO: aaojournal.org/?sf197153774=1

More than 1.3 million people are affected by blood cancer worldwide. September is #BloodCancerAwarenessMonth. At Johnson & Johnson, our commitment to advancing treatments for patients with blood cancers is stronger than ever: janssen.com/oncology/focus…

We’re excited to share how we’re helping to advance cardiology care through our Phase 3 Librexia program at the #ESCCongress this weekend, along with our partner Bristol Myers Squibb.

Advanced Practice Providers (APPs) play a critical role on cancer care teams. Learn more about their impact from a #MultipleMyeloma patient and their care partner in the Make It HAPPen webinar on 9/10 Register for the event in partnership with APSHO: bit.ly/3XwMQ1G

With our decade-plus legacy of pushing the boundaries of innovation in #ProstateCancer care, we aim to address the unmet needs of patients with this disease. This #ProstateCancerAwarenessMonth, learn how we continue to make a difference for these patients: bit.ly/3Xte4Gb

.@Serotiny’s journey is a testament to the power of innovation and collaboration. Discover how the Farlow brothers are transforming cell & gene therapy with cutting-edge technologies. Dive into their remarkable journey below 👇🏾

We are excited to attend #ERSCongress, hosted by the ERS. This annual congress brings together industry experts to showcase the latest advancements in respiratory medicine and disease areas, including #PulmonaryHypertension. Learn more: bit.ly/3XAbfDt

With our latest research in #LungCancer, we’re advancing new options for patients and improving their treatment experience. We look forward to sharing new data on our targeted therapy for patients with #NSCLC at #WCLC24: bit.ly/4dUI9nQ #JNJOncology